Psychedelic Clinical Trials
Find clinical trials studying psilocybin, MDMA, ketamine and other psychedelics. Many trials are actively recruiting participants who haven't found relief from conventional treatments.
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation
Novartis Pharmaceuticals
Ketamine and Kidney Injury in Cardiac Surgery
Mayo Clinic
Psilocybin Therapy for Depression in Bipolar II Disorder
University of California, San Francisco
Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain
NYU Langone Health
Measurement of Serum Inflammatory Markers in Patients Treatment-resistant Depression Given Psilocybin
King's College London
Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder
Johns Hopkins University
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
Yale University
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants
Bristol-Myers Squibb
Ketamine + Cognitive Training for Suicidality in the Medical Setting
Rebecca Price
Pilot Trial of Visual Healing® in Psilocybin-assisted Therapy for Alcohol Use Disorder
Keith Heinzerling
Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)
New York State Psychiatric Institute
Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment
University Hospital, Geneva
Perioperative Lidocaine and Ketamine in Abdominal Surgery
The Cleveland Clinic
Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)
Rennes University Hospital
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
Mayo Clinic
Lysergic Acid Diethylamide (LSD) as Treatment for Cluster Headache
University Hospital, Basel, Switzerland
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
Yale University
Intranasal Ketamine as an Adjunct to Fentanyl for the Prehospital Treatment of Acute Traumatic Pain
Jason McMullan
Imaging SV2A in Mood Disorders
Yale University
BMN 110 US Expanded Access Program
BioMarin Pharmaceutical
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)
Janssen Research & Development, LLC
Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects
GH Research Ireland Limited
The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron
Mayo Clinic
Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants
University Hospital, Basel, Switzerland
A Study Assessing Brain Activity, Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers
MycoMedica Life Sciences PBC
Reducing Pain With Methadone and Ketamine in Liver Transplant
Lahey Clinic
Drug Effects on Mood and Behavior - Expectancy
University of Chicago
Mood Effects of Serotonin Agonists: Depression
University of Chicago
Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)
The University of Texas Health Science Center at San Antonio
Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19
University of Texas at Austin
ESKetamine Low-dose vs Ketamine Low-dose for Severe Acute Pain in Emergency Units, Comparison of PsychodyslEptic Effects
Centre Hospitalier Universitaire de Nice
Psilocybin Brain Stimulation and Imaging Pilot Study
Johns Hopkins University
Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects
University Hospital, Basel, Switzerland
Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV
Nicky Mehtani, MD, MPH
Dance Movement Therapy for Radio-oncological Patients
University of Erlangen-Nürnberg Medical School
Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants
University Hospital, Basel, Switzerland
Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures
Centre Hospitalier Universitaire de Nīmes
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
Cybin IRL Limited
KF2024#1-trial: Esketamine Interaction Study
Helsinki University Central Hospital
Safety for Home Administration of Microdose Psilocybin Use
Johns Hopkins University
Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression
Centre Hospitalier Universitaire de Nīmes
A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer
University of Washington
FMRI of Patients Receiving IV Ketamine for Treatment Resistant Bipolar Depression
Drew Cumming
Ketamine for Methamphetamine Use Disorder
University of Texas Southwestern Medical Center
Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant OCD
Centre for Addiction and Mental Health
Effect of Ketamine, Amitriptyline and Their Combination on Itch
Aalborg University
Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy
Tatiana Aboulafia Brakha
Low-Income Group Psilocybin Assisted Therapy for Depression
Matthew Hicks
Browse by Condition
View all conditions →How to Join a Clinical Trial
Clinical trials are research studies that test new treatments. Participating can give you access to cutting-edge therapies while contributing to medical science. Each trial has specific eligibility criteria based on the research goals.
1. Review
Read the trial details, eligibility criteria, and what participation involves.
2. Contact
Reach out to the study team using the contact information provided.
3. Screen
Complete the screening process to determine if you're eligible.